Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC–MS/MS

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Wei Xu, Hui Yang, Ying Liu et al. · Cancer Cell · 2011 · 2.8K citations · Full text

Molecular Pharmacology, Aldehyde Dehydrogenase, Biochemistry +4

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

María E. Figueroa, Omar Abdel‐Wahab, Chao Lü et al. · Cancer Cell · 2010 · 2.7K citations · Full text

Hematological Malignancy, Somatic Variant, Hypermethylation Phenotype +10

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Patrick S. Ward, Jay Patel, David R. Wise et al. · Cancer Cell · 2010 · 2K citations · Full text

Somatic Variant, Biochemistry, Medicine +10

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.4K citations · Full text